Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) ACHN-490 in Healthy Subjects.

Next Previous
X
Search
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) ACHN-490 in Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plazomicin (Primary)
  • Indications Bacteraemia; Gram-negative infections; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 22 Jan 2019 Results of pooled analysis assessing the population pharmacokinetics for Plazomicin from 7 studies :NCT00822978, NCT01034774,NCT01462136,NCT01514929,NCT01096849,NCT01970371 and NCT02486627 were published in the Antimicrobial Agents and Chemotherapy
    • 28 Apr 2013 Results presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases.
    • 12 Sep 2011 Results published in Antimicrobial Agents and Chemotherapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top